Could this be the secret to Pfizer's rebound strategy?

By Andrew Silver SHANGHAI, June 29 (Reuters) - GLP-1 drugs from Pfizer and Innovent Biologics have passed a preliminary ...

One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow.

AbbVie and Pfizer are taking divergent paths to navigate patent expirations and competition. Dig into their financials, risk ...

Pfizer’s CEO, Albert Bourla, Ph.D., has yet to top the $33 million in compensation that he earned on the coattails of megablockbuster COVID-19 sales in 2022, but a $27.6 million pay package after a ...

Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued S&P 500 Stocks to Buy Right Now. On September 2, Pfizer Inc. (NYSE:PFE) announced a new trial collaboration with Olema Pharmaceuticals for ...

Pfizer (PFE) closed at $24.08 in the latest trading session, marking a -1.19% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.79%. At the same time, the Dow ...

Pfizer is racing towards patent cliffs that will lead to even worse financial results. Vertex Pharmaceuticals is posting strong revenue growth and excellent clinical progress. Pfizer's financial ...

The ruling marks the end of a case that put Alnylam and Pfizer at loggerheads. In its response to the PMCPA, Alnylam accused ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

The sizable yield comes with a concerning footnote. Just look at the rest of the story.

Johnson & Johnson is a global leader in the pharmaceutical and medical device industries. Its key products include ...